Vaccines: DNA

Abstract

From their initial discovery, DNA (deoxyribonucleic acid) vaccines have evolved considerably in the past three decades to become a viable alternative to the traditional active and live attenuated vaccines. While the safety profile of DNA vaccines is highly promising, there still seem to be some looming challenges with their efficiency. A range of modifications have been made to optimise the immunogenicity and functional efficiency of DNA vaccines including plasmid backbone optimisation, delivery methodology, formulation and therapeutic regimen adaptation. Although most of these changes have provided iterative benefits, a more thorough understanding is needed for lasting success.

Key Concepts

  • DNA vaccines offer a novel viable immunisation against infectious diseases and cancers.
  • Plasmid design and adjuvant formulation enhances the DNA vaccine outcomes.
  • Efficient activation of cellular and humoral response dictates the immunogenicity of DNA vaccines.
  • Categorisation of various factors which affect DNA vaccination strategy into ‘five immune forces’.
  • Next‐generation sequencing and mutanome analysis seem to offer promising future prospects to DNA vaccination.

Keywords: DNA vaccine; plasmid; immunogenicity; lymphocytes; cytokines

Figure 1. Overview of various factors affecting DNA vaccine success.
Figure 2. Various parts of a generic plasmid utilised in DNA vaccine.
Figure 3. Overview of the mechanism of induction of immune responses by DNA vaccine.
close

References

Amara S and Tiriveedhi V (2017) The five immune forces impacting DNA‐based cancer immunotherapeutic strategy. International Journal of Molecular Sciences 18 (3 pii: E650).

van den Berg JH, Nujien B, Beijnen JH, et al. (2009) Optimization of intradermal vaccination by DNA tattooing in human skin. Human Gene Therapy 20: 181–189.

Bolton DL, Song K, Wilson RL, et al. (2012) Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunology 5: 41–52.

Chiarella P, Massi E, De Robertis M, et al. (2008) Electroporation of skeletal muscle induces danger signal release and antigen‐presenting cell recruitment independently of DNA vaccine administration. Expert Opinion on Biological Therapy 8: 1645–1657.

Donnelly JJ, Liu MA and Ulmer JB (2000) Antigen presentation and DNA vaccines. American Journal of Respiratory and Critical Care Medicine 162: S190–S193.

Garren H, Ruiz PJ, Watkins TA, et al. (2001) Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15: 15–22.

Germain RN (2010) Vaccines and the future of human immunology. Immunity 33: 441–450.

Jin H, Li Y, Ma Z, et al. (2004) Effect of chemical adjuvants on DNA vaccination. Vaccine 22: 2925–2935.

Koup RA and Douek DC (2011) Vaccine design for CD8 T lymphocyte responses. Cold Spring Harbor Perspectives in Medicine 1: a007252.

Kutzler MA and Weiner DB (2008) DNA vaccines: ready for prime time? Nature Reviews. Genetics 9: 776–788.

Li L, Goedegebuure P, Mardis ER, et al. (2011) Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers (Basel) 3: 4191–4211.

Li L, Saade F and Petrovsky N (2012) The future of human DNA vaccines. Journal of Biotechnology 162: 171–182.

Mutapi F, Billingsley PF and Secor WE (2013) Infection and treatment immunizations for successful parasite vaccines. Trends in Parasitology 29: 135–141.

Qin L, Jiang G, Han J, et al. (2015) Regulatory T cells modulate DNA vaccine immunogenicity at early time via functional CD4(+) T cells and antigen duration. Frontiers in Immunology 6: 510.

Rodriguez F, Harkins S, Redwine JM, et al. (2001) CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope‐specific lysosomal targeting. Journal of Virology 75: 10421–10430.

Rottembourg D, Filippi CM, Bresson D, et al. (2010) Essential role for TLR9 in prime but not prime‐boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. Journal of Immunology 184: 7100–7107.

Saade F and Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Review of Vaccines 11: 189–209.

Seok H, Noh JY, Lee DY, et al. (2017) Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA‐based cationic nanoparticles. Journal of Controlled Release 265: 66–74.

Smith KA (2011) Edward jenner and the small pox vaccine. Frontiers in Immunology 2: 21.

Stoecklinger A, Grieshuber I, Scheiblhofer S, et al. (2007) Epidermal langerhans cells are dispensable for humoral and cell‐mediated immunity elicited by gene gun immunization. Journal of Immunology 179: 886–893.

Tang DC, DeVit M and Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152–154.

Torrieri‐Dramard L, Lambrecht B, Ferreira HL, et al. (2013) Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross‐protective immunity against influenza viruses. Molecular Therapy 19: 602–611.

Ulmer JB, Donnelly JJ, Parker SE, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745–1749.

Wolff JA, Malone RW, Williams P, et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465–1468.

Zhang X, Sharma PK, Peter Goedegebuure S, et al. (2017) Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine 35: 1094–1100.

Further Reading

Lee C, Lee M, Rhee I, et al. (2018) Distinct features of dendritic cell‐based immunotherapy as cancer vaccines. Clin Exp Vaccine Res. 7: 16–23.

Maeng H, Terabe M, Berzofsky JA, et al. (2018) Cancer vaccines: Translation from mice to human clinical trials. Curr Opin Immunol. 51: 111–122.

Roden RBS and Stern PL (2018) Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer 18 (4): 240–254.

Sahin U and Türeci Ö (2018) Personalized vaccines for cancer immunotherapy. Science 359: 1355–1360.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Tiriveedhi, Venkataswarup(May 2018) Vaccines: DNA. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0000492.pub3]